FDA Inspection 1342072 — BrightGene BioMedical Technology Co., Ltd.

BrightGene BioMedical Technology Co., Ltd. — FEI 3012595938

The FDA completed an inspection of BrightGene BioMedical Technology Co., Ltd. on Sep 9, 2026 in Suzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.

Inspection details

Classification
Voluntary Action Indicated (VAI)
End Date
Sep 9, 2026
Fiscal Year
2026
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Suzhou (China)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.